NCT01527591View on ClinicalTrials.gov

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

NAActive, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 1, 2012

Primary Completion Date

December 31, 2023

Study Completion Date

December 30, 2025

Conditions
Infection in Solid Organ Transplant Recipients
Interventions
BIOLOGICAL

Pneumococcal Conjugate Vaccine 13 (PCV13)

A single intramuscular dose of 0.5 mL.

Trial Locations (1)

90095-1752

UCLA, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT01527591 - Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT) | Biotech Hunter | Biotech Hunter